|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
|
US8168383B2
(en)
|
2006-04-14 |
2012-05-01 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
|
EP3266867A1
(en)
*
|
2006-04-14 |
2018-01-10 |
Cell Signaling Technology, Inc. |
Gene defects and mutant alk kinase in human solid tumors
|
|
CA2598893C
(en)
*
|
2006-10-11 |
2012-04-10 |
Astellas Pharma Inc. |
Eml4-alk fusion gene
|
|
CN101466721B
(zh)
*
|
2007-04-13 |
2013-08-21 |
细胞信号技术公司 |
在人实体瘤中的基因缺损和突变体alk激酶
|
|
TWI389893B
(zh)
*
|
2007-07-06 |
2013-03-21 |
Astellas Pharma Inc |
二（芳胺基）芳基化合物
|
|
AU2009215168A1
(en)
*
|
2008-02-12 |
2009-08-20 |
Dana-Farber Cancer Institute |
Fish assay for EML4 and ALK fusion in lung cancer
|
|
JP2009219728A
(ja)
*
|
2008-03-18 |
2009-10-01 |
Daito Giken:Kk |
遊技台
|
|
MX2010012703A
(es)
|
2008-05-21 |
2010-12-21 |
Ariad Pharma Inc |
Derivados fosforosos como inhibidores de cinasa.
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
|
CA2762108A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Insight Genetics, Inc. |
Methods and compositions relating to fusions of alk for diagnosing and treating cancer
|
|
JPWO2011043220A1
(ja)
|
2009-10-06 |
2013-03-04 |
富士レビオ株式会社 |
融合遺伝子の測定方法
|
|
US9175350B2
(en)
*
|
2009-12-22 |
2015-11-03 |
Quest Diagnostics Investments Incorporated |
EML4-ALK translocations in lung cancer
|
|
EP2540822B1
(en)
*
|
2010-02-22 |
2017-05-03 |
Fujirebio Inc. |
Method for identification of oncogene, method for establishment of cell capable of expressing oncogene, and method for screening for oncogene-targeting substance
|
|
US8383793B2
(en)
|
2010-04-15 |
2013-02-26 |
St. Jude Children's Research Hospital |
Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
|
|
TW201202703A
(en)
*
|
2010-04-16 |
2012-01-16 |
Response Genetics Inc |
Primers, probes, methods, and kits for the detection of EML4-ALK variants
|
|
WO2012019132A2
(en)
|
2010-08-06 |
2012-02-09 |
Cell Signaling Technology, Inc. |
Anaplastic lymphoma kinase in kidney cancer
|
|
BR112013003879B1
(pt)
|
2010-08-20 |
2020-12-22 |
Chugai Seiyaku Kabushiki Kaisha |
composição compreendendo compostos tetracíclicos e formulação oralmente administrável que a compreende
|
|
US8962245B2
(en)
|
2010-09-02 |
2015-02-24 |
Kurume University |
Method for producing circular DNA formed from single-molecule DNA
|
|
JP2014005206A
(ja)
*
|
2010-10-22 |
2014-01-16 |
Astellas Pharma Inc |
アリールアミノヘテロ環カルボキサミド化合物
|
|
JP5769952B2
(ja)
*
|
2010-11-12 |
2015-08-26 |
株式会社Ｌｓｉメディエンス |
Ｅｍｌ４−ａｌｋ融合遺伝子の高感度検出方法
|
|
WO2012075318A2
(en)
*
|
2010-12-01 |
2012-06-07 |
Cell Signaling Technology, Inc. |
Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
|
|
BR112013019643B1
(pt)
*
|
2011-02-02 |
2022-04-19 |
Novartis Ag |
Uso de inibidores de álcali
|
|
US20140296181A1
(en)
*
|
2011-04-07 |
2014-10-02 |
Coferon, Inc. |
Methods of modulating oncogenic fusion proteins
|
|
BR112013027734A2
(pt)
|
2011-05-04 |
2017-08-08 |
Ariad Pharma Inc |
compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica
|
|
EP2752486B1
(en)
|
2011-08-31 |
2016-12-28 |
Kurume University |
Method for exclusive selection of circularized dna from monomolecular dna when circularizing dna molecules
|
|
DK2838998T3
(en)
|
2012-04-18 |
2018-01-15 |
Cell Signaling Technology Inc |
EGFR AND ROS1 IN CANCER
|
|
AU2013204563B2
(en)
|
2012-05-05 |
2016-05-19 |
Takeda Pharmaceutical Company Limited |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
|
US9084456B1
(en)
*
|
2012-05-28 |
2015-07-21 |
Jack Zemer |
Linkage for jewelry components
|
|
EP2892536B1
(en)
|
2012-09-06 |
2019-12-18 |
Epizyme, Inc. |
Method of treating leukemia
|
|
CA2894220A1
(en)
*
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
Dot1l inhibitors for use in the treatment of leukemia
|
|
EP2958592A1
(en)
|
2013-02-22 |
2015-12-30 |
F. Hoffmann-La Roche AG |
Methods of treating cancer and preventing drug resistance
|
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
|
JP6534930B2
(ja)
|
2013-07-26 |
2019-06-26 |
公益財団法人がん研究会 |
Ｎｔｒｋ３融合体の検出法
|
|
WO2015064620A1
(ja)
*
|
2013-10-29 |
2015-05-07 |
公益財団法人がん研究会 |
新規融合体及びその検出法
|
|
WO2015064621A1
(ja)
*
|
2013-10-29 |
2015-05-07 |
公益財団法人がん研究会 |
新規融合体及びその検出法
|
|
EP3098312B1
(en)
|
2014-01-24 |
2023-07-19 |
Japanese Foundation For Cancer Research |
Novel fusant and method for detecting same
|
|
CN106458967A
(zh)
|
2014-04-25 |
2017-02-22 |
中外制药株式会社 |
四环化合物的新结晶
|
|
CN106456651A
(zh)
|
2014-04-25 |
2017-02-22 |
中外制药株式会社 |
以高用量含有四环性化合物的制剂
|
|
TWI718102B
(zh)
|
2014-08-08 |
2021-02-11 |
日商中外製藥股份有限公司 |
４環性化合物的非晶質體
|
|
US10597725B2
(en)
*
|
2014-09-01 |
2020-03-24 |
Arkray, Inc. |
Primer reagent for amplifying ALK fusion gene, ALK fusion gene amplification reagent kit including the same, and ALK fusion gene amplification method and ALK fusion gene analysis method using the same
|
|
JP7015171B2
(ja)
|
2016-01-15 |
2022-02-02 |
公益財団法人がん研究会 |
新規融合体及びその検出法
|
|
JP6740172B2
(ja)
*
|
2017-05-02 |
2020-08-12 |
セル・シグナリング・テクノロジー・インコーポレイテツド |
ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
|
|
US12473548B2
(en)
*
|
2018-06-27 |
2025-11-18 |
City Of Hope |
Modification of small RNAs for therapeutic uses
|
|
EP3815688B1
(en)
|
2018-06-29 |
2023-12-06 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition containing poorly-soluble basic medicine
|
|
JP7385191B2
(ja)
*
|
2019-08-30 |
2023-11-22 |
学校法人同志社 |
Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬
|
|
JP2020156481A
(ja)
*
|
2020-04-06 |
2020-10-01 |
セル・シグナリング・テクノロジー・インコーポレイテツド |
ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
|
|
CN118159274A
(zh)
|
2021-10-28 |
2024-06-07 |
中外制药株式会社 |
糖浆剂
|
|
TW202412771A
(zh)
|
2022-07-04 |
2024-04-01 |
日商中外製藥股份有限公司 |
併用醫藥
|
|
CN119789871A
(zh)
|
2022-08-30 |
2025-04-08 |
中外制药株式会社 |
并用药物
|